LB Pharmaceuticals, Inc. (LBRX)
48.80
+0.59
(+1.22%)
USD |
NASDAQ |
Aug 25, 16:00
48.78
-0.02
(-0.04%)
After-Hours: 19:59
LB Pharmaceuticals Shareholders Equity (Quarterly) : 332.35M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 332.35M |
| March 31, 2026 | 378.69M |
| December 31, 2025 | 301.31M |
| September 30, 2025 | 310.22M |
| June 30, 2025 |
| Date | Value |
|---|---|
| March 31, 2025 | |
| December 31, 2024 | 19.70M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | 63.81M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 967.52M |
| Neumora Therapeutics, Inc. | 44.52M |
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 361.69M |
| Total Liabilities (Quarterly) | 29.34M |
| Debt to Equity Ratio | 0.0157 |
| Current Ratio | 15.08 |
| Net Debt Paydown Yield | -0.11% |